|
1.
|
Joehanes R, Ying S, Huan T, Johnson AD, Raghavachari N, Wang R, Liu P, Woodhouse KA, Sen SK, Tanriverdi K, Courchesne P, Freedman JE, O'Donnell CJ, Levy D, Munson PJ. Gene expression signatures of coronary heart disease. Arterioscler Thromb Vasc Biol. 2013 Jun; 33(6):1418-26.
|
|
|
|
|
2.
|
Johnson AD, Hwang SJ, Voorman A, Morrison A, Peloso GM, Hsu YH, Thanassoulis G, Newton-Cheh C, Rogers IS, Hoffmann U, Freedman JE, Fox CS, Psaty BM, Boerwinkle E, Cupples LA, O'Donnell CJ. Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the framingham heart study. Circulation. 2013 Feb 19; 127(7):799-810.
|
|
|
|
|
3.
|
Risitano A, Beaulieu LM, Vitseva O, Freedman JE. Platelets and platelet-like particles mediate intercellular RNA transfer. Blood. 2012 Jun 28; 119(26):6288-95.
|
|
|
|
|
4.
|
Freedman JE. Appreciating and mitigating bleeding risk. Circulation. 2012 Apr 10; 125(14):e548-50.
|
|
|
|
|
5.
|
Rowley JW, Finn AV, French PA, Jennings LK, Bluestein D, Gross PL, Freedman JE, Steinhubl SR, Zimmerman GA, Becker RC, Dauerman HL, Smyth SS. Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. Circ Cardiovasc Interv. 2012 Apr; 5(2):296-304.
|
|
|
|
|
6.
|
Freedman JE. A platelet transcriptome revolution. Blood. 2011 Oct 6; 118(14):3760-1.
|
|
|
|
|
7.
|
Beaulieu LM, Freedman JE. Inflammation & the platelet histone trap. Blood. 2011 Aug 18; 118(7):1714-5.
|
|
|
|
|
8.
|
Farb MG, Bigornia S, Mott M, Tanriverdi K, Morin KM, Freedman JE, Joseph L, Hess DT, Apovian CM, Vita JA, Gokce N. Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. J Am Coll Cardiol. 2011 Jul 12; 58(3):232-7.
|
|
|
|
|
9.
|
Beaulieu LM, Lin E, Morin KM, Tanriverdi K, Freedman JE. Regulatory effects of TLR2 on megakaryocytic cell function. Blood. 2011 Jun 2; 117(22):5963-74.
|
|
|
|
|
10.
|
Tomasson G, Lavalley M, Tanriverdi K, Finkielman JD, Davis JC, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Stone JH, Freedman JE, Merkel PA. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol. 2011 Jun; 38(6):1048-54.
|
|
|
|
|
11.
|
Gersh BJ, Freedman JE, Granger CB. [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. Rev Esp Cardiol. 2011 Apr; 64(4):260-8.
|
|
|
|
|
12.
|
Freedman JE, Iafrati HF. Use of genetics and transcriptomics in the diagnosis and treatment of coronary artery disease. Rev Esp Cardiol. 2010 Oct; 63(10):1123-6.
|
|
|
|
|
13.
|
Freedman JE, Vitseva O, Tanriverdi K. The role of the blood transcriptome in innate inflammation and stroke. Ann N Y Acad Sci. 2010 Oct; 1207:41-5.
|
|
|
|
|
14.
|
Freedman JE, Larson MG, Tanriverdi K, O'Donnell CJ, Morin K, Hakanson AS, Vasan RS, Johnson AD, Iafrati MD, Benjamin EJ. Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation. 2010 Jul 13; 122(2):119-29.
|
|
|
|
|
15.
|
Chakrabarti S, Freedman JE. Review: Nutriceuticals as antithrombotic agents. Cardiovasc Ther. 2010 Aug; 28(4):227-35.
|
|
|
|
|
16.
|
Chakrabarti S, Rizvi M, Morin K, Garg R, Freedman JE. The role of CD40L and VEGF in the modulation of angiogenesis and inflammation. Vascul Pharmacol. 2010 Sep-Oct; 53(3-4):130-7.
|
|
|
|
|
17.
|
Beaulieu LM, Freedman JE. p38: signaling improved platelet storage? Blood. 2010 Mar 4; 115(9):1665-6.
|
|
|
|
|
18.
|
Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost. 2010 Apr; 8(4):817-27.
|
|
|
|
|
19.
|
Beaulieu LM, Freedman JE. The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. Thromb Res. 2010 Mar; 125(3):205-9.
|
|
|
|
|
20.
|
Chakrabarti S, Beaulieu LM, Reyelt LA, Iafrati MD, Freedman JE. M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice. J Thromb Thrombolysis. 2009 Nov; 28(4):394-400.
|
|
|
|
|
21.
|
Freedman JE, Gersh BJ. New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy. Circulation. 2009 Sep 22; 120(12):1024-6.
|
|
|
|
|
22.
|
Rex S, Beaulieu LM, Perlman DH, Vitseva O, Blair PS, McComb ME, Costello CE, Freedman JE. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost. 2009 Jul; 102(1):97-110.
|
|
|
|
|
23.
|
Beaulieu LM, Freedman JE. NFkappaB regulation of platelet function: no nucleus, no genes, no problem? J Thromb Haemost. 2009 Aug; 7(8):1329-32.
|
|
|
|
|
24.
|
Faxon DP, Freedman JE. Facts and controversies of aspirin and clopidogrel therapy. Am Heart J. 2009 Mar; 157(3):412-22.
|
|
|
|
|
25.
|
Chakrabarti S, Rizvi M, Pathak D, Kirber MT, Freedman JE. Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. Immunol Lett. 2009 Feb 21; 122(2):170-84.
|
|
|
|
|
26.
|
Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med. 2009 Jan 22; 360(4):411-3.
|
|
|
|
|
27.
|
Lin E, Freedman JE, Beaulieu LM. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther. 2009; 27(2):117-23.
|
|
|
|
|
28.
|
Blair P, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, Chakrabarti S, Hayashi C, Genco CA, Iafrati M, Freedman JE. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res. 2009 Feb 13; 104(3):346-54.
|
|
|
|
|
29.
|
Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med. 2008 Dec; 14(12):530-8.
|
|
|
|
|
30.
|
Keaney JF, Lipinska I, Larson MG, Dupuis J, Freedman JE, Hamburg NM, Massaro JM, Rong J, Sutherland P, Vita JA, Vasan RS, Benjamin EJ. Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study. Am Heart J. 2008 Nov; 156(5):1003-1009.e1.
|
|
|
|
|
31.
|
Tanriverdi K, Freedman JE. Blood and cardiovascular disease: the promise and limitations of gene expression analysis. Circ Cardiovasc Genet. 2008 Oct; 1(1):7-9.
|
|
|
|
|
32.
|
Kleiman NS, Freedman JE, Tracy PB, Furie BC, Bray PF, Rao SV, Phillips DR, Storey RF, Rusconi CP, French PA, Steinhubl SR, Becker RC. Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. Platelets. 2008 Jun; 19(4):239-51.
|
|
|
|
|
33.
|
Ector H, Lancellotti P, Roberts WC, Wenger NK, Moss AJ, Smith ER, Borer JS, Eagle KA, Freedman J, Krum H, Lang C, Remme WJ, Piper HM, White CJ, Loscalzo J, Marbán E, Sobel BE, Roberts R, Rahimtoola SH, Camm AJ, Van de Werf F, Swedberg K, Timmis AD, Stone KS, Zipes DP, Iosselani DG, Taylor AJ, Rosen MR, Grines CL, DeMaria AN, Narula J, King SB, Wagner GS, Saksena S, Pearlman AS, Bodnar E, Emery RW, Cohn LH, van der Wall EE, Abdulla RI, Lesch M, Alfonso F, Ekroth R. A statement on ethics from the HEART Group. JACC Cardiovasc Imaging. 2008 May; 1(3):410-2.
|
|
|
|
|
34.
|
Blair P, Freedman JE. Aspirin resistance in atherosclerosis. Curr Atheroscler Rep. 2008 Apr; 10(2):149-57.
|
|
|
|
|
35.
|
Vanichakarn P, Blair P, Wu C, Freedman JE, Chakrabarti S. Neutrophil CD40 enhances platelet-mediated inflammation. Thromb Res. 2008; 122(3):346-58.
|
|
|
|
|
36.
|
Vitseva OI, Tanriverdi K, Tchkonia TT, Kirkland JL, McDonnell ME, Apovian CM, Freedman J, Gokce N. Inducible Toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue. Obesity (Silver Spring). 2008 May; 16(5):932-7.
|
|
|
|
|
37.
|
Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease, and the vasculature. Vascul Pharmacol. 2008 Apr-Jun; 48(4-6):143-9.
|
|
|
|
|
38.
|
Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):s11-6.
|
|
|
|
|
39.
|
Freedman JE. Promoting ethical conduct in the publication of research. Cardiovasc Ther. 2008; 26(2):89-90.
|
|
|
|
|
40.
|
Freedman JE. Transcriptomics: new targets for diagnosing and treating cardiovascular disease. Cardiovasc Ther. 2008; 26(3):179-81.
|
|
|
|
|
41.
|
Chakrabarti S, Blair P, Wu C, Freedman JE. Redox state of dipyridamole is a critical determinant for its beneficial antioxidant and antiinflammatory effects. J Cardiovasc Pharmacol. 2007 Oct; 50(4):449-57.
|
|
|
|
|
42.
|
Freedman JE. Heritability, platelet function, and aspirin: a link established but cause unknown. Circulation. 2007 May 15; 115(19):2468-70.
|
|
|
|
|
43.
|
Chakrabarti S, Blair P, Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem. 2007 Jun 22; 282(25):18307-17.
|
|
|
|
|
44.
|
Schmugge M, Bang KW, Blanchette VS, Albisetti M, Connolly BL, Freedman J, Rand ML. Platelet activation and von Willebrand factor binding to platelets in newborn infants with central venous lines. Acta Haematol. 2007; 117(3):145-8.
|
|
|
|
|
45.
|
Tziros C, Freedman JE. The many antithrombotic actions of nitric oxide. Curr Drug Targets. 2006 Oct; 7(10):1243-51.
|
|
|
|
|
46.
|
Yang H, Reheman A, Chen P, Zhu G, Hynes RO, Freedman J, Wagner DD, Ni H. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost. 2006 Oct; 4(10):2230-7.
|
|
|
|
|
47.
|
Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation. 2006 Jun 27; 113(25):2865-7.
|
|
|
|
|
48.
|
Freedman JE. Resistance training: does it alter lytic potential? J Cardiopulm Rehabil. 2006 Mar-Apr; 26(2):84-5.
|
|
|
|
|
49.
|
Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation. 2005 Oct 25; 112(17):2725-34.
|
|
|
|
|
50.
|
Vitseva O, Varghese S, Chakrabarti S, Folts JD, Freedman JE. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. J Cardiovasc Pharmacol. 2005 Oct; 46(4):445-51.
|
|
|
|
|
51.
|
Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005 Sep 20; 46(6):986-93.
|
|
|
|
|
52.
|
Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, Freedman JE. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol. 2005 Nov 15; 96(10):1365-9.
|
|
|
|
|
53.
|
Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005 Nov; 25(11):2428-34.
|
|
|
|
|
54.
|
Chakrabarti S, Vitseva O, Iyu D, Varghese S, Freedman JE. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther. 2005 Nov; 315(2):494-500.
|
|
|
|
|
55.
|
Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost. 2005 May; 3(5):875-83.
|
|
|
|
|
56.
|
Iafrati MD, Vitseva O, Tanriverdi K, Blair P, Rex S, Chakrabarti S, Varghese S, Freedman JE. Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am J Physiol Heart Circ Physiol. 2005 Apr; 288(4):H1627-32.
|
|
|
|
|
57.
|
Albers AR, Varghese S, Vitseva O, Vita JA, Freedman JE. The antiinflammatory effects of purple grape juice consumption in subjects with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2004 Nov; 24(11):e179-80.
|
|
|
|
|
58.
|
Vitseva O, Flockhart DA, Jin Y, Varghese S, Freedman JE. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther. 2005 Mar; 312(3):1144-50.
|
|
|
|
|
59.
|
Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting. Circulation. 2004 Jun 1; 109(21):2672-9.
|
|
|
|
|
60.
|
Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design. Circulation. 2004 Jun 1; 109(21):e302-4.
|
|
|
|
|
61.
|
Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. Circulation. 2004 Jun 1; 109(21):e305-7.
|
|
|
|
|
62.
|
Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med. 2004; 5(3):156-63.
|
|
|
|
|
63.
|
Urquidi-Macdonald M, Mager DE, Mascelli MA, Frederick B, Freedman J, Fitzgerald DJ, Kleiman NS, Abernethy DR. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clin Pharmacol Ther. 2004 Jan; 75(1):60-9.
|
|
|
|
|
64.
|
Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release. Thromb Res. 2004; 113(3-4):225-33.
|
|
|
|
|
65.
|
Clutton P, Miermont A, Freedman JE. Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler Thromb Vasc Biol. 2004 Jan; 24(1):187-92.
|
|
|
|
|
66.
|
Freedman JE, Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J Thromb Haemost. 2003 Jun; 1(6):1183-8.
|
|
|
|
|
67.
|
Freedman JE. High-fat diets and cardiovascular disease: are nutritional supplements useful? J Am Coll Cardiol. 2003 May 21; 41(10):1750-2.
|
|
|
|
|
68.
|
Freedman JE. CD40-CD40L and platelet function: beyond hemostasis. Circ Res. 2003 May 16; 92(9):944-6.
|
|
|
|
|
69.
|
Freedman JE. CD40 ligand--assessing risk instead of damage? N Engl J Med. 2003 Mar 20; 348(12):1163-5.
|
|
|
|
|
70.
|
Freedman JE, Becker RC, Adams JE, Borzak S, Jesse RL, Newby LK, O'Gara P, Pezzullo JC, Kerber R, Coleman B, Broderick J, Yasuda S, Cannon C. Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation. 2002 Nov 12; 106(20):2623-9.
|
|
|
|
|
71.
|
Freedman JE. Nitrated lipids: defining their bioactivity. Circ Res. 2002 Sep 6; 91(5):371-2.
|
|
|
|
|
72.
|
Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics. 2002 Jul; 12(5):407-13.
|
|
|
|
|
73.
|
Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation. 2002 May 7; 105(18):2130-2.
|
|
|
|
|
74.
|
Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clin Pharmacol Ther. 2002 Mar; 71(3):186-95.
|
|
|
|
|
75.
|
Rand ML, Wang H, Mody M, Chu I, Treutiger I, Nguyen A, Packham MA, Freedman J. Concurrent measurement of the survival of two populations of rabbit platelets labeled with either two PKH lipophilic dyes or two concentrations of biotin. Cytometry. 2002 Feb 1; 47(2):111-7.
|
|
|
|
|
76.
|
Freedman J, Mascelli MA, Pezzullo JC, Barnathan ES, Frederick B, Jordan RE, Abernethy DR. Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects. Am Heart J. 2002 Jan; 143(1):87-94.
|
|
|
|
|
77.
|
Clutton P, Folts JD, Freedman JE. Pharmacological control of platelet function. Pharmacol Res. 2001 Oct; 44(4):255-64.
|
|
|
|
|
78.
|
Freedman JE, Parker C, Li L, Perlman JA, Frei B, Ivanov V, Deak LR, Iafrati MD, Folts JD. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001 Jun 12; 103(23):2792-8.
|
|
|
|
|
79.
|
Parker C, Vita JA, Freedman JE. Soluble adhesion molecules and unstable coronary artery disease. Atherosclerosis. 2001 Jun; 156(2):417-24.
|
|
|
|
|
80.
|
Freedman JE. Thrombin, thrombomodulin, and extracellular signal-regulated kinases regulating cellular proliferation. Circ Res. 2001 Apr 13; 88(7):651-3.
|
|
|
|
|
81.
|
Upchurch GR, Goodman DG, Willoughby SR, Zhang YY, Welch GN, Freedman JE, Ye S, Costello CE, Loscalzo J. Heparin reacts with and inactivates nitric oxide. J Cardiovasc Pharmacol Ther. 2001 Apr; 6(2):163-73.
|
|
|
|
|
82.
|
Freedman JE, Keaney JF. Vitamin E inhibition of platelet aggregation is independent of antioxidant activity. J Nutr. 2001 Feb; 131(2):374S-7S.
|
|
|
|
|
83.
|
Freedman JE, Li L, Sauter R, Keaney JF JR. alpha-Tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release. FASEB J. 2000 Dec; 14(15):2377-9.
|
|
|
|
|
84.
|
Leytin V, Mody M, Semple JW, Garvey B, Freedman J. Quantification of platelet activation status by analyzing P-selectin expression. Biochem Biophys Res Commun. 2000 Jul 5; 273(2):565-70.
|
|
|
|
|
85.
|
Song S, Freedman J, Mody M, Lazarus AH. Porcine von Willebrand factor and thrombin induce the activation of c-Jun amino-terminal kinase (JNK/SAPK) whereas only thrombin induces activation of extracellular signal-related kinase 2 (ERK2) in human platelets. Br J Haematol. 2000 Jun; 109(4):851-6.
|
|
|
|
|
86.
|
Leytin V, Mody M, Semple JW, Garvey B, Freedman J. Flow cytometric parameters for characterizing platelet activation by measuring P-selectin (CD62) expression: theoretical consideration and evaluation in thrombin-treated platelet populations. Biochem Biophys Res Commun. 2000 Mar 5; 269(1):85-90.
|
|
|
|
|
87.
|
Bang KW, Speck ER, Blanchette VS, Freedman J, Semple JW. Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. Blood. 2000 Mar 1; 95(5):1735-42.
|
|
|
|
|
88.
|
Loscalzo J, Freedman J, Inbal A, Keaney JF, Michelson AD, Vita JA. Nitric oxide insufficiency and arterial thrombosis. Trans Am Clin Climatol Assoc. 2000; 111:158-63.
|
|
|
|
|
89.
|
Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, Vavva F, Brand N, Michelson A, Trolliet M, Loscalzo J, Inbal A. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol. 1999 Aug; 19(8):2017-23.
|
|
|
|
|
90.
|
Freedman JE, Sauter R, Battinelli EM, Ault K, Knowles C, Huang PL, Loscalzo J. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res. 1999 Jun 25; 84(12):1416-21.
|
|
|
|
|
91.
|
Keaney JF, Simon DI, Freedman JE. Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB J. 1999 Jun; 13(9):965-75.
|
|
|
|
|
92.
|
Mody M, Lazarus AH, Semple JW, Freedman J. Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. Transfus Med. 1999 Jun; 9(2):147-54.
|
|
|
|
|
93.
|
Lieberthal W, Fuhro R, Freedman JE, Toolan G, Loscalzo J, Valeri CR. O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J Pharmacol Exp Ther. 1999 Mar; 288(3):1278-87.
|
|
|
|
|
94.
|
Semple JW, Speck ER, Cosgrave D, Lazarus AH, Blanchette VS, Freedman J. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood. 1999 Jan 15; 93(2):713-20.
|
|
|
|
|
95.
|
Freedman JE, Keaney JF. Nitric oxide and superoxide detection in human platelets. Methods Enzymol. 1999; 301:61-70.
|
|
|
|
|
96.
|
Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF, Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation. 1998 Oct 13; 98(15):1481-6.
|
|
|
|
|
97.
|
Vita JA, Keaney JF, Raby KE, Morrow JD, Freedman JE, Lynch S, Koulouris SN, Hankin BR, Frei B. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol. 1998 Apr; 31(5):980-6.
|
|
|
|
|
98.
|
Chang H, Mody M, Lazarus AH, Ofosu F, Garvey MB, Blanchette V, Teitel J, Freedman J. Platelet activation induced by porcine factor VIII (Hyate:C). Am J Hematol. 1998 Mar; 57(3):200-5.
|
|
|
|
|
99.
|
Liu Z, Rudd MA, Freedman JE, Loscalzo J. S-Transnitrosation reactions are involved in the metabolic fate and biological actions of nitric oxide. J Pharmacol Exp Ther. 1998 Feb; 284(2):526-34.
|
|
|
|
|
100.
|
Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997 Jul 15; 100(2):350-6.
|
|
|
|
|
101.
|
Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997 Jul 4; 272(27):17012-7.
|
|
|
|
|
102.
|
Semple JW, Siminovitch KA, Mody M, Milev Y, Lazarus AH, Wright JF, Freedman J. Flow cytometric analysis of platelets from children with the Wiskott-Aldrich syndrome reveals defects in platelet development, activation and structure. Br J Haematol. 1997 Jun; 97(4):747-54.
|
|
|
|
|
103.
|
Upchurch GR, Welch GN, Freedman JE, Fabian AJ, Pigazzi A, Scribner AM, Alpert CS, Keaney JF, Loscalzo J. High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells. Circulation. 1997 Apr 15; 95(8):2115-21.
|
|
|
|
|
104.
|
Freedman JE, Loscalzo J. Endothelial dysfunction and atherothrombotic occlusive disease. Drugs. 1997; 54 Suppl 3:41-9; discussion 49-50.
|
|
|
|
|
105.
|
Kühne T, Ryan G, Blanchette V, Semple JW, Hornstein A, Mody M, Chang W, McWhirter L, Freedman J. Platelet-surface glycoproteins in healthy and preeclamptic mothers and their newborn infants. Pediatr Res. 1996 Dec; 40(6):876-80.
|
|
|
|
|
106.
|
Freedman JE, Farhat JH, Loscalzo J, Keaney JF. alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation. 1996 Nov 15; 94(10):2434-40.
|
|
|
|
|
107.
|
Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996 Feb 15; 97(4):979-87.
|
|
|
|
|
108.
|
Loscalzo J, Pasche B, Ouimet H, Freedman JE. Platelets and plasminogen activation. Thromb Haemost. 1995 Jul; 74(1):291-3.
|
|
|
|
|
109.
|
Freedman JE, Frei B, Welch GN, Loscalzo J. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest. 1995 Jul; 96(1):394-400.
|
|
|
|
|
110.
|
Freedman JE, Fabian A, Loscalzo J. Impaired EDRF production by endothelial cells exposed to fibrin monomer and FDP. Am J Physiol. 1995 Feb; 268(2 Pt 1):C520-6.
|
|
|
|
|
111.
|
Liu L, Freedman J, Hornstein A, Fenton JW, Ofosu FA. Thrombin binding to platelets and their activation in plasma. Br J Haematol. 1994 Nov; 88(3):592-600.
|
|
|
|
|
112.
|
Ouimet H, Freedman JE, Loscalzo J. Kinetics and mechanism of platelet-surface plasminogen activation by tissue-type plasminogen activator. Biochemistry. 1994 Mar 15; 33(10):2970-6.
|
|
|
|
|
113.
|
Loscalzo J, Freedman J, Rudd MA, Barsky-Vasserman I, Vaughan DE. Unsaturated fatty acids enhance low density lipoprotein uptake and degradation by peripheral blood mononuclear cells. Arteriosclerosis. 1987 Sep-Oct; 7(5):450-5.
|
|
|
|
|
114.
|
Loscalzo J, Freedman J. Purification and characterization of human platelet glutathione-S-transferase. Blood. 1986 Jun; 67(6):1595-9.
|
|
|
|
